Except, that future is the present. A company called Recursion Pharmaceuticals (NASDAQ: RXRX) is doing it. Using its access to 65 petabytes' (65 million gigabytes) worth of biological, chemical, and ...

By now, we all know about Palantir, the one-of-a-kind juggernaut meme stock that can’t be stopped. It’s part sledgehammer, ...

Duquesne Family Office's lead investor dumped two of the most prominent AI stocks for a company that thrived during the COVID-19 pandemic.

Palantir’s revenue growth accelerated to 48% and its adjusted operating margin stands at 46%. That’s an extraordinary ...

Palantir topped $1 billion in quarterly revenue for the first time. Considering the company's extreme valuation, it may be ...

Palantir’s eccentric CEO has led one of the most controversial companies in Silicon Valley to unprecedented success.

Discover why Palantir Technologies Inc. and Navitas Semiconductor Corporation are key players in the AI trade. Click to ...

Based on reports and issued price targets from two select Wall Street analysts, these foundational pieces to the evolution of ...

Palantir's moonshot is paying off with ETF tailwinds. A bunch of thematic and innovation-themed ETFs are bullish, and they're riding the wave.

Palantir Technologies stock (NASDAQ: PLTR) has had a remarkable run this year, more than doubling since early January to ...

Palantir earnings top $1B in Q2 2025 amid AI boom, fueling stock rally and driving massive revenue growth in U.S. commercial ...

Wedbush analyst Dan Ives raised his price target on Palantir Technologies Inc. (NYSE: PLTR) to $200, citing "hyper growth ...